Abstract:Key PointsThe Hedgehog signalling pathway has diverse functions in animal development and tissue homeostasis. Dysregulation of the pathway has been implicated in several developmental syndromes and cancers.The production of Hedgehog (HH) ligands involves autoproteolytic cleavage and the addition of lipid moieties such as cholesterol and palmitic acid. Several dedicated proteins are required for the secretion of the ligand.Novel mechanisms involving ligand multimerization, complex formation with additional soluble proteins and association with components of the extracellular matrix, such as the heparan sulphate proteoglycans, have been proposed to explain the dispersion of lipidated HH proteins through tissues.Signal transduction requires a number of transmembrane proteins, most notably Patched 1 (PTC) and Smoothened (SMO). The mechanism by which the signal is transduced from PTC to SMO is unclear. Strikingly, in vertebrates, but not Drosophila melanogaster, signal transduction requires the primary cilia of cells, identifying a function for this previously enigmatic organelle.Intracellularly, signalling involves Suppressor of Fu (SUFU), the kinesin proteins Costal 2 (Cos2) in D. melanogaster and KIF7 in vertebrates and several kinases. Signalling culminates with the regulation of the D. melanogaster Cubitus interruptus (Ci) and vertebrate GLI families of transcription factors. HH signalling converts the Ci and GLI proteins from transcriptional repressors to activators by inhibiting their proteolytic cleavage.The various functions of HH signalling have predominately been ascribed to its regulation of gene expression, and the relevant transcriptional networks are beginning to be dissected. Recently, however, non-canonical branches to the signalling pathway have been found, and these might contribute to some HH functions.HH signalling regulates the survival and proliferation of tissue progenitor and stem populations. This function is linked to its role in tumour formation. Several small-molecule antagonists and agonists that target SMO have been identified, and these show promise in the treatment of HH-related pathologies. In 2012, the approval of the Food and Drug Administration (FDA) was obtained for the first drug that targets HH signalling in the skin cancer basal cell carcinoma.

Beyond cyclopamine: Targeting Hedgehog signaling for cancer intervention

Current Status of Hedgehog Signaling Inhibitors

Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation

Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance

MEKK2 and MEKK3 Suppress Hedgehog Pathway-Dependent Medulloblastoma by Inhibiting GLI1 Function

Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling

Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy

Cyclopamine Blocked the Growth of Colorectal Cancer SW116 Cells by Modulating Some Target Genes of Gli1 in Vitro

Small-molecule modulators of the Sonic Hedgehog signaling pathway

Hedgehog signaling controls cytotoxic T cell migration in the tumour microenvironment.

Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease

The mechanisms of Hedgehog signalling and its roles in development and disease

Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers

Hedgehog Signaling Pathway and Autophagy in Cancer

Hedgehog Signaling in Human Hepatocellular Carcinoma

Hedgehog Pathway Inhibitors against Tumor Microenvironment

Novel-smoothened Inhibitors for Therapeutic Targeting of Naïve and Drug-Resistant Hedgehog Pathway-Driven Cancers.

Suppression of Growth and Migration by Blocking the Hedgehog Signaling Pathway in Gastric Cancer Cells

Therapeutic potential of hedgehog signaling in advanced cancer types

Hedgehog Pathway Blockade Inhibits Melanoma Cell Growth in Vitro and in Vivo

Pharmacological modulation of Sonic Hedgehog signaling pathways in Angiogenesis: A mechanistic perspective